How are Patient Outcomes Impacted by Value Based Health Care Delivery for Inflammatory Bowel Diseases

2017 ◽  
Vol 152 (5) ◽  
pp. S790
Author(s):  
Aria Zand ◽  
Elizabeth Aredas ◽  
Natalie E. Duran ◽  
Courtney A. DiNicola ◽  
Precious Lacey ◽  
...  
Keyword(s):  
Health Care ◽  
Patient Outcomes ◽  
Health Care Delivery ◽  
Inflammatory Bowel Diseases ◽  
Care Delivery ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals P354 The effect of value based health care delivery for inflammatory bowel diseases on outcomes of patients

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S257-S257
Author(s):  
A. Zand ◽  
E. Aredas ◽  
N. Duran ◽  
C. DiNicola ◽  
P. Lacey ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Delivery ◽  
Inflammatory Bowel Diseases ◽  
Care Delivery ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals A Nationwide 2010–2012 Analysis of U.S. Health Care Utilization in Inflammatory Bowel Diseases

2014 ◽  
Vol 20 (10) ◽  
pp. 1747-1753 ◽  
Author(s):  
Welmoed K. van Deen ◽  
Martijn G. H. van Oijen ◽  
Kelly D. Myers ◽  
Adriana Centeno ◽  
William Howard ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Inflammatory Bowel Diseases ◽  
Care Utilization ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan

2018 ◽  
Vol 1 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Shota Saito ◽  
Kyoko Nakazawa ◽  
Kenji Suzuki ◽  
Takashi Ishikawa ◽  
Kouhei Akazawa
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Inflammatory Bowel Diseases ◽  
Claims Data ◽  
Cost Driver ◽  
Medication Cost ◽  
Administrative Claims ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Care Costs

Anti-tumor necrosis factor-α (anti-TNFα) agents are used for induction and maintenance of remission in patients with inflammatory bowel diseases (IBD). However, biologic drugs present a large economic burden on health insurance systems. We aimed to estimate the mean annual health care cost per patient with IBD and cost contribution of anti-TNFα agents. We performed an analysis of patients with Crohn’s disease (CD) and ulcerative colitis (UC) based on a large-scale administrative claims database constructed by Japan Medical Data Center (JMDC) Co. Ltd., comprising inpatient, outpatient, and pharmacy claims data. We evaluated all claims from 1 April 2013 through 31 March 2016. Descriptive statistics were used to measure median health care costs paid per member per year (PMPY) and the relative cost contribution of anti-TNFα agents. A total 1405 patients with CD and 5771 with UC were included. Median costs PMPY were approximately six times higher for CD than UC (JPY 1,957,320 and JPY 278,760, respectively). Medication cost for anti-TNFα agents was the main cost driver, accounting for 59.9% and 17.8% of the total costs for CD and UC, respectively. In Japan, costs for anti-TNFα agents have resulted in drug costs exceeding inpatient costs for IBD. Optimized use of anti-TNFα agents and introduction of biosimilars for anti-TNFα agents can be expected to substantially reduce the health care costs of IBD.

308 The Impact of a Value-Based Health Care in Inflammatory Bowel Diseases on Health Care Utilization

2016 ◽  
Vol 150 (4) ◽  
pp. S70-S71 ◽  
Author(s):  
Welmoed K. van Deen ◽  
Martha Skup ◽  
Adriana Centeno ◽  
Natalie E. Duran ◽  
Precious Lacey ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Inflammatory Bowel Diseases ◽  
Care Utilization ◽  
A Value ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Impact

scholarly journals Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases

2014 ◽  
Vol 8 (9) ◽  
pp. 927-935 ◽  
Author(s):  
William J. Sandborn ◽  
Stephen Hanauer ◽  
Gert Van Assche ◽  
Julián Panés ◽  
Stephanie Wilson ◽  
...  
Keyword(s):  
Patient Outcomes ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document